首页 > 最新文献

Journal of Basic and Clinical Physiology and Pharmacology最新文献

英文 中文
Evaluation of the serum level of CTRP-3 and CTRP-6 in patients with Hashimoto's disease and correlation with thyroid hormones and lipid profile. 桥本病患者血清CTRP-3和CTRP-6水平的评价及其与甲状腺激素和血脂的相关性
Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2025-01-21 eCollection Date: 2025-01-01 DOI: 10.1515/jbcpp-2024-0060
Rafal Sameer Al-Abboody, Nadia Heydari, Mohsen Saravani, Shahin Nosaratzehi, Hamideh Akbari, Seyyed Mehdi Jafari

Objectives: Numerous studies show that the adipokines play a role in on the thyroid axis. The aim of this study was the evaluation of serum level of CTRP-3 and CTRP-6 as a member of the adipokines family in patients with Hashimoto's.

Methods: The levels of CTRP-3 and CTRP-6 were evaluated with enzyme-linked immunosorbent assay in 70 subjects (35 newly diagnosed Hashimoto's thyroiditis and 35 healthy subjects). Their relationship with the thyroid hormone and some biochemical factors was analyzed.

Results: The levels of CTRP3 and CTRP6 in patients with Hashimoto's disease were higher than those in the control group (p<0.05). There was a significant positive correlation between CTRP3 and TSH levels (r=0.286 and p=0.017). There was a significant relationship between CTRP3 and Fasting Blood Sugar (r=0.249 and p=0.038). There was a significant inverse negative correlation between CTRP6 levels and T3 (r=-0.269 and p=0.024), and T4 (r=-0.272 and p=0.023). Moreover, there was a significant positive correlation between CTRP6 serum levels and TSH serum levels (r=0.397 and p=0.001). There was a significant positive correlation between CTRP6 levels and Cholesterol (r=0.351 and p=0.003), and LDL (r=-0.244 and p=0.042).

Conclusions: Finally, our results demonstrated that serum levels of CTRP3 and CTRP6 are higher in patients with Hashimoto's compared to the control group and probably play a role in the pathogenesis of Hashimoto's thyroiditis.

目的:大量研究表明脂肪因子在甲状腺轴上起作用。本研究的目的是评估桥本氏症患者血清中作为脂肪因子家族成员的CTRP-3和CTRP-6的水平。方法:应用酶联免疫吸附法测定70例(35例新诊断的桥本甲状腺炎患者和35例健康人)血清CTRP-3和CTRP-6水平。分析了它们与甲状腺激素及一些生化因素的关系。结果:桥本病患者血清CTRP3和CTRP6水平高于对照组(p结论:最后,我们的研究结果表明,桥本病患者血清CTRP3和CTRP6水平高于对照组,可能在桥本甲状腺炎的发病机制中起作用。
{"title":"Evaluation of the serum level of CTRP-3 and CTRP-6 in patients with Hashimoto's disease and correlation with thyroid hormones and lipid profile.","authors":"Rafal Sameer Al-Abboody, Nadia Heydari, Mohsen Saravani, Shahin Nosaratzehi, Hamideh Akbari, Seyyed Mehdi Jafari","doi":"10.1515/jbcpp-2024-0060","DOIUrl":"10.1515/jbcpp-2024-0060","url":null,"abstract":"<p><strong>Objectives: </strong>Numerous studies show that the adipokines play a role in on the thyroid axis. The aim of this study was the evaluation of serum level of CTRP-3 and CTRP-6 as a member of the adipokines family in patients with Hashimoto's.</p><p><strong>Methods: </strong>The levels of CTRP-3 and CTRP-6 were evaluated with enzyme-linked immunosorbent assay in 70 subjects (35 newly diagnosed Hashimoto's thyroiditis and 35 healthy subjects). Their relationship with the thyroid hormone and some biochemical factors was analyzed.</p><p><strong>Results: </strong>The levels of CTRP3 and CTRP6 in patients with Hashimoto's disease were higher than those in the control group (p<0.05). There was a significant positive correlation between CTRP3 and TSH levels (r=0.286 and p=0.017). There was a significant relationship between CTRP3 and Fasting Blood Sugar (r=0.249 and p=0.038). There was a significant inverse negative correlation between CTRP6 levels and T3 (r=-0.269 and p=0.024), and T4 (r=-0.272 and p=0.023). Moreover, there was a significant positive correlation between CTRP6 serum levels and TSH serum levels (r=0.397 and p=0.001). There was a significant positive correlation between CTRP6 levels and Cholesterol (r=0.351 and p=0.003), and LDL (r=-0.244 and p=0.042).</p><p><strong>Conclusions: </strong>Finally, our results demonstrated that serum levels of CTRP3 and CTRP6 are higher in patients with Hashimoto's compared to the control group and probably play a role in the pathogenesis of Hashimoto's thyroiditis.</p>","PeriodicalId":15352,"journal":{"name":"Journal of Basic and Clinical Physiology and Pharmacology","volume":" ","pages":"61-67"},"PeriodicalIF":0.0,"publicationDate":"2025-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143006162","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Exploring the therapeutic potential of GLP-1 receptor agonists in the management of obstructive sleep apnea: a comprehensive review. 探索GLP-1受体激动剂在阻塞性睡眠呼吸暂停治疗中的治疗潜力:一项全面的综述。
Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2025-01-14 eCollection Date: 2025-01-01 DOI: 10.1515/jbcpp-2024-0193
Amruth Akhil Alluri, Merin Mohan Kurien, Nikhil Patel Pokar, Alekhya Madarapu, Sreeja Sadam, Nikhitha Puvvala, Rajmohan Seetharaman

Obstructive Sleep Apnea (OSA) is a prevalent sleep disorder marked by repeated episodes of partial or complete upper airway obstruction during sleep, which leads to intermittent hypoxia and fragmented sleep. These disruptions negatively impact cardiovascular health, metabolic function, and overall quality of life. Obesity is a major modifiable risk factor for OSA, as it contributes to both anatomical and physiological mechanisms that increase the likelihood of airway collapse during sleep. While continuous positive airway pressure (CPAP) therapy remains the gold standard for OSA treatment, its limitations - particularly issues with patient adherence - underscore the need for alternative or adjunct therapeutic options. One such option is the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), which are widely recognized for their ability to reduce body weight and improve metabolic health. Emerging evidence suggests that GLP-1 RAs may offer therapeutic benefits in managing OSA, particularly by addressing obesity, a key contributor to the condition. This narrative review seeks to explore the role of GLP-1 RAs in the treatment of OSA, evaluating their efficacy in reducing OSA severity and discussing their broader clinical implications for future research and practice.

阻塞性睡眠呼吸暂停(OSA)是一种常见的睡眠障碍,其特征是睡眠中反复发作的部分或完全上呼吸道阻塞,导致间歇性缺氧和睡眠片段化。这些干扰会对心血管健康、代谢功能和整体生活质量产生负面影响。肥胖是阻塞性睡眠呼吸暂停的一个主要可改变的危险因素,因为它有助于增加睡眠时气道塌陷的可能性的解剖和生理机制。虽然持续气道正压(CPAP)治疗仍然是OSA治疗的金标准,但其局限性-特别是患者依从性问题-强调了替代或辅助治疗方案的必要性。其中一个选择是使用胰高血糖素样肽-1受体激动剂(GLP-1 RAs),它被广泛认为具有减轻体重和改善代谢健康的能力。新出现的证据表明,GLP-1 RAs可能在控制OSA方面具有治疗益处,特别是通过解决肥胖问题,这是导致OSA的关键因素。本文旨在探讨GLP-1 RAs在OSA治疗中的作用,评估其降低OSA严重程度的功效,并讨论其对未来研究和实践的更广泛的临床意义。
{"title":"Exploring the therapeutic potential of GLP-1 receptor agonists in the management of obstructive sleep apnea: a comprehensive review.","authors":"Amruth Akhil Alluri, Merin Mohan Kurien, Nikhil Patel Pokar, Alekhya Madarapu, Sreeja Sadam, Nikhitha Puvvala, Rajmohan Seetharaman","doi":"10.1515/jbcpp-2024-0193","DOIUrl":"10.1515/jbcpp-2024-0193","url":null,"abstract":"<p><p>Obstructive Sleep Apnea (OSA) is a prevalent sleep disorder marked by repeated episodes of partial or complete upper airway obstruction during sleep, which leads to intermittent hypoxia and fragmented sleep. These disruptions negatively impact cardiovascular health, metabolic function, and overall quality of life. Obesity is a major modifiable risk factor for OSA, as it contributes to both anatomical and physiological mechanisms that increase the likelihood of airway collapse during sleep. While continuous positive airway pressure (CPAP) therapy remains the gold standard for OSA treatment, its limitations - particularly issues with patient adherence - underscore the need for alternative or adjunct therapeutic options. One such option is the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), which are widely recognized for their ability to reduce body weight and improve metabolic health. Emerging evidence suggests that GLP-1 RAs may offer therapeutic benefits in managing OSA, particularly by addressing obesity, a key contributor to the condition. This narrative review seeks to explore the role of GLP-1 RAs in the treatment of OSA, evaluating their efficacy in reducing OSA severity and discussing their broader clinical implications for future research and practice.</p>","PeriodicalId":15352,"journal":{"name":"Journal of Basic and Clinical Physiology and Pharmacology","volume":" ","pages":"13-25"},"PeriodicalIF":0.0,"publicationDate":"2025-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142978591","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy and safety of resmetirom in MASLD and MASH: network meta-analysis of randomized clinical trials. 雷司替罗在MASLD和MASH中的疗效和安全性:随机临床试验的网络荟萃分析。
Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2025-01-09 eCollection Date: 2025-01-01 DOI: 10.1515/jbcpp-2024-0140
Hazem Ayesh, Azizullah Beran, Sajida Suhail, Suhail Ayesh, Kevin Niswender

Introduction: Metabolic-Associated Steatohepatitis-Related Liver Disease (MASLD) and, its progressive form, Metabolic-Associated Steatohepatitis (MASH) pose significant global health challenges. Current therapeutic strategies targeting metabolic abnormalities have shown promise but lack specificity for the liver. Thyroid hormones, particularly thyroid hormone receptor beta (THR-β) agonists like resmetirom, offer a targeted approach to liver-related pathways.

Content: A network meta-analysis (NMA) comparing different doses of resmetirom to placebo for MASLD and MASH was conducted. PubMed, Scopus, Cochrane, and Web of Science were searched for relevant randomized controlled trials (RCTs). Efficacy outcomes included histological, radiological, and biochemical parameters, while safety outcomes comprised adverse events and treatment discontinuation.

Summary: Resmetirom demonstrated dose-dependent efficacy in histological and radiological assessments, with the 100 mg dose showing superior MASH resolution and hepatic fat reduction. Biochemical markers indicated improved liver function with resmetirom treatment. However, adverse events, particularly diarrhea and nausea, were more prevalent in the resmetirom group, leading to higher treatment discontinuation rates.

Outlook: Resmetirom shows promise as a therapeutic option for MASLD and MASH management, with significant improvements in liver health parameters. However, safety concerns warrant careful monitoring in clinical practice. Further research is needed to optimize its long-term safety and efficacy.

代谢性脂肪性肝炎相关肝病(MASLD)及其进展形式代谢性脂肪性肝炎(MASH)构成了重大的全球健康挑战。目前针对代谢异常的治疗策略已经显示出希望,但对肝脏缺乏特异性。甲状腺激素,特别是甲状腺激素受体β (THR-β)激动剂,如雷司替龙,提供了肝脏相关途径的靶向途径。内容:进行了一项网络荟萃分析(NMA),比较了不同剂量的雷美替米与安慰剂治疗MASLD和MASH。检索PubMed、Scopus、Cochrane和Web of Science相关的随机对照试验(RCTs)。疗效结果包括组织学、放射学和生化参数,而安全性结果包括不良事件和停止治疗。总结:瑞司替龙在组织学和放射学评估中显示出剂量依赖性疗效,100 mg剂量显示出优越的MASH溶解和肝脏脂肪减少。生化指标显示雷司美康治疗后肝功能有所改善。然而,不良事件,特别是腹泻和恶心,在雷司替罗组更普遍,导致更高的治疗停药率。展望:瑞斯替龙有望作为MASLD和MASH管理的治疗选择,在肝脏健康参数方面有显著改善。然而,在临床实践中,安全问题需要仔细监测。需要进一步研究以优化其长期安全性和有效性。
{"title":"Efficacy and safety of resmetirom in MASLD and MASH: network meta-analysis of randomized clinical trials.","authors":"Hazem Ayesh, Azizullah Beran, Sajida Suhail, Suhail Ayesh, Kevin Niswender","doi":"10.1515/jbcpp-2024-0140","DOIUrl":"10.1515/jbcpp-2024-0140","url":null,"abstract":"<p><strong>Introduction: </strong>Metabolic-Associated Steatohepatitis-Related Liver Disease (MASLD) and, its progressive form, Metabolic-Associated Steatohepatitis (MASH) pose significant global health challenges. Current therapeutic strategies targeting metabolic abnormalities have shown promise but lack specificity for the liver. Thyroid hormones, particularly thyroid hormone receptor beta (THR-β) agonists like resmetirom, offer a targeted approach to liver-related pathways.</p><p><strong>Content: </strong>A network meta-analysis (NMA) comparing different doses of resmetirom to placebo for MASLD and MASH was conducted. PubMed, Scopus, Cochrane, and Web of Science were searched for relevant randomized controlled trials (RCTs). Efficacy outcomes included histological, radiological, and biochemical parameters, while safety outcomes comprised adverse events and treatment discontinuation.</p><p><strong>Summary: </strong>Resmetirom demonstrated dose-dependent efficacy in histological and radiological assessments, with the 100 mg dose showing superior MASH resolution and hepatic fat reduction. Biochemical markers indicated improved liver function with resmetirom treatment. However, adverse events, particularly diarrhea and nausea, were more prevalent in the resmetirom group, leading to higher treatment discontinuation rates.</p><p><strong>Outlook: </strong>Resmetirom shows promise as a therapeutic option for MASLD and MASH management, with significant improvements in liver health parameters. However, safety concerns warrant careful monitoring in clinical practice. Further research is needed to optimize its long-term safety and efficacy.</p>","PeriodicalId":15352,"journal":{"name":"Journal of Basic and Clinical Physiology and Pharmacology","volume":" ","pages":"3-11"},"PeriodicalIF":0.0,"publicationDate":"2025-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142948885","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Risk factor assessment for post-thrombolytic coronary angiogram normalcy in young myocardial infarction patients. 年轻心肌梗死患者溶栓后冠状动脉造影正常的危险因素评估。
Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2024-12-31 eCollection Date: 2025-01-01 DOI: 10.1515/jbcpp-2024-0064
Venkatramani Mahadevan, Abirami Karuppiah, Shravan Venkatraman

Objectives: Acute myocardial infarction is a critical medical condition that poses a significant risk to life. It is distinguished by the abrupt cessation of blood flow to a specific segment of the cardiac muscle. Acute myocardial infarction accounts for more than 15 % of global mortality annually.

Methods and results: A total of 433 young patients admitted with acute coronary syndrome - myocardial infarction underwent thrombolysis with fibrin specific agents followed by underwent diagnostic coronary angiogram between 01.09.2021 and 31.10.2022. The odds ratio showed a value of 1.973, which is much higher than the individuals with diabetes (0.306). Young individuals (25.9 %) with hypertension have a greater chance of recovery by thrombolysis.

Conclusions: The factors that contribute for the myocardial infarction should be recognized and addressed. Recognizing and addressing these risk factors through education, lifestyle modifications, and early intervention are crucial for preventing myocardial infarction and promoting good health.

目的:急性心肌梗死是一种严重危及生命的疾病。它的特点是血液突然停止流向心肌的特定部分。急性心肌梗死每年占全球死亡率的15% %以上。方法与结果:在2021年9月1日至2022年10月31日期间,共433例入院的急性冠状动脉综合征-心肌梗死的年轻患者接受了纤维蛋白特异性药物溶栓治疗,并进行了诊断性冠状动脉造影。比值比为1.973,远高于糖尿病个体(0.306)。年轻高血压患者(25.9 %)通过溶栓恢复的机会更大。结论:对心肌梗死的相关因素应予以认识和重视。通过教育、改变生活方式和早期干预认识和解决这些危险因素对于预防心肌梗死和促进身体健康至关重要。
{"title":"Risk factor assessment for post-thrombolytic coronary angiogram normalcy in young myocardial infarction patients.","authors":"Venkatramani Mahadevan, Abirami Karuppiah, Shravan Venkatraman","doi":"10.1515/jbcpp-2024-0064","DOIUrl":"10.1515/jbcpp-2024-0064","url":null,"abstract":"<p><strong>Objectives: </strong>Acute myocardial infarction is a critical medical condition that poses a significant risk to life. It is distinguished by the abrupt cessation of blood flow to a specific segment of the cardiac muscle. Acute myocardial infarction accounts for more than 15 % of global mortality annually.</p><p><strong>Methods and results: </strong>A total of 433 young patients admitted with acute coronary syndrome - myocardial infarction underwent thrombolysis with fibrin specific agents followed by underwent diagnostic coronary angiogram between 01.09.2021 and 31.10.2022. The odds ratio showed a value of 1.973, which is much higher than the individuals with diabetes (0.306). Young individuals (25.9 %) with hypertension have a greater chance of recovery by thrombolysis.</p><p><strong>Conclusions: </strong>The factors that contribute for the myocardial infarction should be recognized and addressed. Recognizing and addressing these risk factors through education, lifestyle modifications, and early intervention are crucial for preventing myocardial infarction and promoting good health.</p>","PeriodicalId":15352,"journal":{"name":"Journal of Basic and Clinical Physiology and Pharmacology","volume":"36 1","pages":"51-59"},"PeriodicalIF":0.0,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143065890","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Quality by design: how poor adherence to guidelines holds back urological app innovation. 设计质量:对指导方针的不遵守如何阻碍了泌尿外科应用程序的创新。
Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2024-12-13 eCollection Date: 2025-01-01 DOI: 10.1515/jbcpp-2024-0205
Emanuele Capasso, Mariagrazia Marisei, Ferdinando Fusco, Enrico Sicignano, Felice Crocetto
{"title":"Quality by design: how poor adherence to guidelines holds back urological app innovation.","authors":"Emanuele Capasso, Mariagrazia Marisei, Ferdinando Fusco, Enrico Sicignano, Felice Crocetto","doi":"10.1515/jbcpp-2024-0205","DOIUrl":"10.1515/jbcpp-2024-0205","url":null,"abstract":"","PeriodicalId":15352,"journal":{"name":"Journal of Basic and Clinical Physiology and Pharmacology","volume":" ","pages":"1-2"},"PeriodicalIF":0.0,"publicationDate":"2024-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142813362","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A cross-sectional study on the effects of physical activity on hand grip strength in type 2 diabetes mellitus patients. 关于体育锻炼对 2 型糖尿病患者手部握力影响的横断面研究。
Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2024-11-28 eCollection Date: 2025-01-01 DOI: 10.1515/jbcpp-2024-0176
Praveena Meyyazhagan, Thamaraiselvi Kanagaraj, Nachal Annamalai

Objectives: The pervasiveness of type 2 diabetes mellitus (T2DM) is rapidly increasing worldwide, with physical inactivity being one of the major risk factors. Hand grip strength (HGS) is an important indicator of overall physical functioning and has been associated with various health-related outcomes. The purpose of this study was to investigate the impact of physical activity on the HGS of patients with type 2 diabetes mellitus (T2DM). Furthermore, it scrutinizes the relationship between physical activity and HGS in terms of sex.

Methods: A cross-sectional study including a total of 140 patients with T2DM was performed. Physical activity levels were assessed via the International Physical Activity Questionnaire (IPAQ). HGS was measured via a Camry digital handgrip dynamometer. Statistical analysis was performed via SPSS software, and statistical approaches such as ANOVA, Pearson correlation and t tests were used.

Results: The results of this research will contribute to the detection of the influence of physical activity and its association with HGS. These findings reveal that physical activity has a significant effect on HGS and that there is a positive correlation between physical activity and increased hand grip strength in individuals with T2DM.

Conclusions: The outcomes offer valuable insights into physical activity and muscle strength, which can aid in the early detection of physical disability. The findings of this study will be valuable for healthcare providers and professionals to suggest relevant physical activities for diabetic patients.

目的:2 型糖尿病(T2DM)的发病率在全球范围内迅速上升,而缺乏运动是主要的风险因素之一。手部握力(HGS)是衡量整体身体机能的重要指标,并与各种健康相关结果有关。本研究旨在探讨体力活动对 2 型糖尿病(T2DM)患者手部握力的影响。此外,本研究还从性别角度探讨了体力活动与 HGS 之间的关系:方法:研究人员对 140 名 T2DM 患者进行了横断面研究。体力活动水平通过国际体力活动问卷(IPAQ)进行评估。HGS通过Camry数字手握式测力计进行测量。统计分析通过 SPSS 软件进行,采用方差分析、皮尔逊相关性和 t 检验等统计方法:本研究的结果将有助于发现体育锻炼的影响及其与 HGS 的关联。这些研究结果表明,体育锻炼对 HGS 有显著影响,体育锻炼与 T2DM 患者手部握力的增加呈正相关:研究结果为体力活动和肌肉力量提供了有价值的见解,有助于早期发现肢体残疾。这项研究的结果对于医疗服务提供者和专业人士为糖尿病患者提出相关体育活动建议很有价值。
{"title":"A cross-sectional study on the effects of physical activity on hand grip strength in type 2 diabetes mellitus patients.","authors":"Praveena Meyyazhagan, Thamaraiselvi Kanagaraj, Nachal Annamalai","doi":"10.1515/jbcpp-2024-0176","DOIUrl":"10.1515/jbcpp-2024-0176","url":null,"abstract":"<p><strong>Objectives: </strong>The pervasiveness of type 2 diabetes mellitus (T2DM) is rapidly increasing worldwide, with physical inactivity being one of the major risk factors. Hand grip strength (HGS) is an important indicator of overall physical functioning and has been associated with various health-related outcomes. The purpose of this study was to investigate the impact of physical activity on the HGS of patients with type 2 diabetes mellitus (T2DM). Furthermore, it scrutinizes the relationship between physical activity and HGS in terms of sex.</p><p><strong>Methods: </strong>A cross-sectional study including a total of 140 patients with T2DM was performed. Physical activity levels were assessed via the International Physical Activity Questionnaire (IPAQ). HGS was measured via a Camry digital handgrip dynamometer. Statistical analysis was performed via SPSS software, and statistical approaches such as ANOVA, Pearson correlation and t tests were used.</p><p><strong>Results: </strong>The results of this research will contribute to the detection of the influence of physical activity and its association with HGS. These findings reveal that physical activity has a significant effect on HGS and that there is a positive correlation between physical activity and increased hand grip strength in individuals with T2DM.</p><p><strong>Conclusions: </strong>The outcomes offer valuable insights into physical activity and muscle strength, which can aid in the early detection of physical disability. The findings of this study will be valuable for healthcare providers and professionals to suggest relevant physical activities for diabetic patients.</p>","PeriodicalId":15352,"journal":{"name":"Journal of Basic and Clinical Physiology and Pharmacology","volume":" ","pages":"27-37"},"PeriodicalIF":0.0,"publicationDate":"2024-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142729014","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Corrigendum to: 6-OHDA mediated neurotoxicity in SH-SY5Y cellular model of Parkinson disease suppressed by pretreatment with hesperidin through activating L-type calcium channels. 更正:在帕金森病 SH-SY5Y 细胞模型中使用橙皮甙预处理可通过激活 L 型钙通道抑制 6-OHDA 介导的神经毒性。
Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2024-11-18 eCollection Date: 2024-11-01 DOI: 10.1515/jbcpp-2024-0122
Leila Elyasi, Mehrdad Jahanshahi, S B Jameie, Hatef Ghasemi Hamid Abadi, Emsehgol Nikmahzar, Masoumeh Khalili, Melika Jameie, Mana Jameie
{"title":"Corrigendum to: 6-OHDA mediated neurotoxicity in SH-SY5Y cellular model of Parkinson disease suppressed by pretreatment with hesperidin through activating L-type calcium channels.","authors":"Leila Elyasi, Mehrdad Jahanshahi, S B Jameie, Hatef Ghasemi Hamid Abadi, Emsehgol Nikmahzar, Masoumeh Khalili, Melika Jameie, Mana Jameie","doi":"10.1515/jbcpp-2024-0122","DOIUrl":"10.1515/jbcpp-2024-0122","url":null,"abstract":"","PeriodicalId":15352,"journal":{"name":"Journal of Basic and Clinical Physiology and Pharmacology","volume":" ","pages":"377"},"PeriodicalIF":0.0,"publicationDate":"2024-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142681946","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effect of omega-3 fatty acids supplementation on muscle mass, fat mass, and visceral fat of hemodialysis patients; A randomized clinical trial. 补充欧米伽-3 脂肪酸对血液透析患者肌肉质量、脂肪质量和内脏脂肪的影响;随机临床试验。
Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2024-11-14 Print Date: 2024-11-26 DOI: 10.1515/jbcpp-2024-0148
Saheb Abbas Torki, Zahra Roumi, Atefeh Tahavorgar, Zahra Salimi, Saeideh Mohammadi, Soheila Shekari, Zahra Saeedirad, Arezoo Amjadi, Pouya Mirzaee, Hanieh Shafaei, Bojlul Bahar, Fatemeh Mofidi, Masoud Khosravi, Saeid Doaei, Maryam Gholamalizadeh

Objectives: Several studies demonstrated the benefits of omega-3 fatty acids supplementation in chronic kidney disease (CKD) patients. The objective of this study was to investigate the effect of omega-3 fatty acids supplementation in body composition, specifically on the lean body mass and fat mass in hemodialysis patients.

Methods: In this randomized, double-blind, placebo-controlled clinical trial, a total of 120 end-stage renal disease (ESRD) patients were randomly allocated into two groups. The intervention group has taken three grams of omega-3 fatty acids daily while the placebo group received three grams of medium chain triglycerides (MCT) as a placebo for a total of 2 months. The changes in the body mass index (BMI) and body composition (fat mass, muscle, and visceral fat) were assessed at baseline and following the intervention.

Results: No significant difference was found in the mean of BMI, FAT, muscle, and visceral fat in the intervention group compared to the control group after the intervention. After two months of omega-3 fatty acid supplementation, the study found no statistically significant impact of omega-3 fatty acids supplementation on various indices of body composition. The effect of ω-3 supplementation in reducing visceral fat was close to significant (p=0.08).

Conclusions: This study suggests that there is currently inadequate evidence to support the effect of omega-3 fatty acid supplementation in improving anthropometric measurements in patients with CKD, except a partial effect on visceral fat. Further large-scale and long-term clinical trials are needed to confirm the present results.

目的:多项研究表明,慢性肾脏病(CKD)患者补充ω-3脂肪酸有益。本研究旨在探讨补充欧米伽-3 脂肪酸对身体组成的影响,特别是对血液透析患者瘦体重和脂肪量的影响:在这项随机、双盲、安慰剂对照临床试验中,共有 120 名终末期肾病(ESRD)患者被随机分配到两组。干预组每天服用 3 克欧米伽-3 脂肪酸,而安慰剂组则服用 3 克中链甘油三酯(MCT)作为安慰剂,共服用 2 个月。在基线和干预后,对体重指数(BMI)和身体成分(脂肪量、肌肉和内脏脂肪)的变化进行了评估:结果:干预后,干预组的体重指数、脂肪、肌肉和内脏脂肪的平均值与对照组相比无明显差异。在补充ω-3脂肪酸两个月后,研究发现补充ω-3脂肪酸对身体成分的各种指数没有明显的统计学影响。补充ω-3对减少内脏脂肪的影响接近显著(p=0.08):本研究表明,除了对内脏脂肪有部分影响外,目前还没有足够的证据支持补充ω-3脂肪酸对改善慢性肾脏病患者人体测量指标的效果。需要进一步开展大规模的长期临床试验来证实本研究结果。
{"title":"Effect of omega-3 fatty acids supplementation on muscle mass, fat mass, and visceral fat of hemodialysis patients; A randomized clinical trial.","authors":"Saheb Abbas Torki, Zahra Roumi, Atefeh Tahavorgar, Zahra Salimi, Saeideh Mohammadi, Soheila Shekari, Zahra Saeedirad, Arezoo Amjadi, Pouya Mirzaee, Hanieh Shafaei, Bojlul Bahar, Fatemeh Mofidi, Masoud Khosravi, Saeid Doaei, Maryam Gholamalizadeh","doi":"10.1515/jbcpp-2024-0148","DOIUrl":"10.1515/jbcpp-2024-0148","url":null,"abstract":"<p><strong>Objectives: </strong>Several studies demonstrated the benefits of omega-3 fatty acids supplementation in chronic kidney disease (CKD) patients. The objective of this study was to investigate the effect of omega-3 fatty acids supplementation in body composition, specifically on the lean body mass and fat mass in hemodialysis patients.</p><p><strong>Methods: </strong>In this randomized, double-blind, placebo-controlled clinical trial, a total of 120 end-stage renal disease (ESRD) patients were randomly allocated into two groups. The intervention group has taken three grams of omega-3 fatty acids daily while the placebo group received three grams of medium chain triglycerides (MCT) as a placebo for a total of 2 months. The changes in the body mass index (BMI) and body composition (fat mass, muscle, and visceral fat) were assessed at baseline and following the intervention.</p><p><strong>Results: </strong>No significant difference was found in the mean of BMI, FAT, muscle, and visceral fat in the intervention group compared to the control group after the intervention. After two months of omega-3 fatty acid supplementation, the study found no statistically significant impact of omega-3 fatty acids supplementation on various indices of body composition. The effect of ω-3 supplementation in reducing visceral fat was close to significant (p=0.08).</p><p><strong>Conclusions: </strong>This study suggests that there is currently inadequate evidence to support the effect of omega-3 fatty acid supplementation in improving anthropometric measurements in patients with CKD, except a partial effect on visceral fat. Further large-scale and long-term clinical trials are needed to confirm the present results.</p>","PeriodicalId":15352,"journal":{"name":"Journal of Basic and Clinical Physiology and Pharmacology","volume":" ","pages":"347-352"},"PeriodicalIF":0.0,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142620961","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Immediate effect of sunlight exposure through blue glass on blood pressure in hypertensive patients: a randomized controlled trial. 通过蓝色玻璃照射阳光对高血压患者血压的直接影响:随机对照试验。
Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2024-11-13 eCollection Date: 2024-11-01 DOI: 10.1515/jbcpp-2024-0081
Deepa Yoganathan, Maheshkumar Kuppusamy, Edmin Christa, Saran Murugan, Vijayabharathi Elangovan, Preetha Jayakumar, Sangamithraa Rammohan

Objective: Hypertension affects approximately 1.28 billion adults worldwide, driving the search for integrative therapeutic approaches alongside conventional treatments. While chromotherapy, particularly blue light exposure, has historical roots in traditional medicine and its specific impact on blood pressure regulation remains understudied. So, the present study aims to investigate the immediate impact of exposure to blue glass through sunlight on blood pressure in hypertensive individuals.

Methods: This randomized controlled trial was carried out with a sample of 60 hypertensive patients, who were divided into two groups: a study group that received blue glass exposure for 20 min and a control group that received exposure to colourless glass. The primary outcome measures were systolic and diastolic blood pressure, pulse rate, and oxygen saturation levels.

Results: The results of the study revealed statistically significant differences in systolic blood pressure (p=0.006) and pulse rate (p=0.005) after the intervention in the study group and no such changes were noted in the control group.

Conclusions: The findings of this study suggest that blue glass exposure has a significant impact on reducing blood pressure and pulse rate in hypertensive patients, indicating its potential use as a integrative treatment in the management of hypertension.

目标: 全球约有 12.8 亿成年人患有高血压,这促使人们在寻求传统治疗方法的同时,也在寻求综合治疗方法。虽然色光疗法,尤其是蓝光照射,在传统医学中有着悠久的历史,但其对血压调节的具体影响仍未得到充分研究。因此,本研究旨在调查通过阳光照射蓝色玻璃对高血压患者血压的直接影响:这项随机对照试验以 60 名高血压患者为样本,将他们分为两组:研究组接受 20 分钟的蓝色玻璃照射,对照组接受无色玻璃照射。主要结果指标为收缩压和舒张压、脉搏和血氧饱和度:研究结果表明,干预后研究组的收缩压(p=0.006)和脉搏(p=0.005)在统计学上有显著差异,而对照组没有发现此类变化:本研究结果表明,接触蓝玻璃对降低高血压患者的血压和脉搏率有显著影响,这表明蓝玻璃有可能作为一种综合疗法用于高血压的治疗。
{"title":"Immediate effect of sunlight exposure through blue glass on blood pressure in hypertensive patients: a randomized controlled trial.","authors":"Deepa Yoganathan, Maheshkumar Kuppusamy, Edmin Christa, Saran Murugan, Vijayabharathi Elangovan, Preetha Jayakumar, Sangamithraa Rammohan","doi":"10.1515/jbcpp-2024-0081","DOIUrl":"10.1515/jbcpp-2024-0081","url":null,"abstract":"<p><strong>Objective: </strong>Hypertension affects approximately 1.28 billion adults worldwide, driving the search for integrative therapeutic approaches alongside conventional treatments. While chromotherapy, particularly blue light exposure, has historical roots in traditional medicine and its specific impact on blood pressure regulation remains understudied<b>.</b> So, the present study aims to investigate the immediate impact of exposure to blue glass through sunlight on blood pressure in hypertensive individuals.</p><p><strong>Methods: </strong>This randomized controlled trial was carried out with a sample of 60 hypertensive patients, who were divided into two groups: a study group that received blue glass exposure for 20 min and a control group that received exposure to colourless glass. The primary outcome measures were systolic and diastolic blood pressure, pulse rate, and oxygen saturation levels.</p><p><strong>Results: </strong>The results of the study revealed statistically significant differences in systolic blood pressure (p=0.006) and pulse rate (p=0.005) after the intervention in the study group and no such changes were noted in the control group.</p><p><strong>Conclusions: </strong>The findings of this study suggest that blue glass exposure has a significant impact on reducing blood pressure and pulse rate in hypertensive patients, indicating its potential use as a integrative treatment in the management of hypertension.</p>","PeriodicalId":15352,"journal":{"name":"Journal of Basic and Clinical Physiology and Pharmacology","volume":" ","pages":"371-374"},"PeriodicalIF":0.0,"publicationDate":"2024-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142621007","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Choroidal and retinal alteration after long-term use of tadalafil: a prospective non-randomized clinical trial. 长期服用他达拉非后脉络膜和视网膜的改变:一项前瞻性非随机临床试验。
Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2024-11-13 eCollection Date: 2024-11-01 DOI: 10.1515/jbcpp-2024-0118
Luca D'Andrea, Gianluigi Califano, Marco Abate, Marco Capece, Claudia Collà Ruvolo, Felice Crocetto, Maria Laura Passaro, Gilda Cennamo, Ciro Costagliola

Objectives: The purpose of this study is to investigate choroidal and retinal vascular features in patients taking PDE5is by measuring dynamic vascular alterations and neurostructural features of the retina before and after oral tadalafil administration.

Methods: The current clinical research involved 22 patients treated with tadalafil 20 mg on alternate days (OAD) after nerve-sparing robotic radical prostatectomy (NS-RARP) for prostate cancer. Patients underwent SD-OCT to assess ganglion cell complex (GCC), retinal nerve fiber layer (RNFL), and subfoveal choroidal thickness (SFCT), as well as OCTA to assess superficial capillary plexus (SCP), deep capillary plexus (DCP), choriocapillaris (CC), foveal avascular zone (FAZ), and radial peripapillary capillary thickness (RPC). All patients were evaluated at baseline (t0), and 3 (t1) and 6 (t2) months after the use of oral tadalafil.

Results: A statistically significant reduction in DCP and CC vessel density was found at t2 compared to baseline. According to the SFCT parameter, a statistically significant increase was observed from t0 to t1, and from t1 to t2. GCC parameter increased at t2 compared to baseline in a statistically significant way. No statistically significant differences were recorded between t0, t1 and t2 for the SCP, RPC, FAZ area, RNFL parameter.

Conclusions: Retinal and optic disc toxicity may be detected using modifications of capillary vessel density. Further studies are needed to detect the possible progression or regression of ocular or systemic vascular complications in long-term follow-up.

研究目的:本研究旨在通过测量口服他达拉非前后视网膜的动态血管改变和神经结构特征,研究服用 PDE5is 患者的脉络膜和视网膜血管特征:目前的临床研究涉及22名前列腺癌保神经机器人根治性前列腺切除术(NS-RARP)后隔日(OAD)服用他达拉非20毫克的患者。患者接受 SD-OCT 评估神经节细胞复合体 (GCC)、视网膜神经纤维层 (RNFL) 和眼底脉络膜厚度 (SFCT),并接受 OCTA 评估浅层毛细血管丛 (SCP)、深层毛细血管丛 (DCP)、绒毛膜 (CC)、眼窝无血管区 (FAZ) 和径向毛细血管周围厚度 (RPC)。对所有患者进行了基线(t0)、口服他达拉非后3个月(t1)和6个月(t2)的评估:结果:与基线相比,在第 2 个月时,DCP 和 CC 血管密度出现了统计学意义上的明显降低。根据 SFCT 参数,从 t0 到 t1,以及从 t1 到 t2,均出现了统计学意义上的显著增加。与基线相比,GCC 参数在 t2 阶段有明显的统计学增长。SCP、RPC、FAZ 面积和 RNFL 参数在 t0、t1 和 t2 之间没有明显的统计学差异:结论:通过改变毛细血管密度可以检测视网膜和视盘毒性。还需要进一步研究,以便在长期随访中检测眼部或全身血管并发症的进展或消退情况。
{"title":"Choroidal and retinal alteration after long-term use of tadalafil: a prospective non-randomized clinical trial.","authors":"Luca D'Andrea, Gianluigi Califano, Marco Abate, Marco Capece, Claudia Collà Ruvolo, Felice Crocetto, Maria Laura Passaro, Gilda Cennamo, Ciro Costagliola","doi":"10.1515/jbcpp-2024-0118","DOIUrl":"10.1515/jbcpp-2024-0118","url":null,"abstract":"<p><strong>Objectives: </strong>The purpose of this study is to investigate choroidal and retinal vascular features in patients taking PDE5is by measuring dynamic vascular alterations and neurostructural features of the retina before and after oral tadalafil administration.</p><p><strong>Methods: </strong>The current clinical research involved 22 patients treated with tadalafil 20 mg on alternate days (OAD) after nerve-sparing robotic radical prostatectomy (NS-RARP) for prostate cancer. Patients underwent SD-OCT to assess ganglion cell complex (GCC), retinal nerve fiber layer (RNFL), and subfoveal choroidal thickness (SFCT), as well as OCTA to assess superficial capillary plexus (SCP), deep capillary plexus (DCP), choriocapillaris (CC), foveal avascular zone (FAZ), and radial peripapillary capillary thickness (RPC). All patients were evaluated at baseline (t0), and 3 (t1) and 6 (t2) months after the use of oral tadalafil.</p><p><strong>Results: </strong>A statistically significant reduction in DCP and CC vessel density was found at t2 compared to baseline. According to the SFCT parameter, a statistically significant increase was observed from t0 to t1, and from t1 to t2. GCC parameter increased at t2 compared to baseline in a statistically significant way. No statistically significant differences were recorded between t0, t1 and t2 for the SCP, RPC, FAZ area, RNFL parameter.</p><p><strong>Conclusions: </strong>Retinal and optic disc toxicity may be detected using modifications of capillary vessel density. Further studies are needed to detect the possible progression or regression of ocular or systemic vascular complications in long-term follow-up.</p>","PeriodicalId":15352,"journal":{"name":"Journal of Basic and Clinical Physiology and Pharmacology","volume":" ","pages":"361-369"},"PeriodicalIF":0.0,"publicationDate":"2024-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142620960","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of Basic and Clinical Physiology and Pharmacology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1